An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.003 trial
Inclusion Criteria:
Exclusion Criteria:
Kralove, Czechia
Hyderabaad, India
Kerala, India
Kelantan, Malaysia
Gauteng, South Africa
Kaohsiung Hsien, Taiwan
Kwei-Shan, Taiwan
Ubonratchathani, Thailand